NHS Wales Approves Biogen’s Plegridy for Relapsing Remitting MS
Relapsing remitting multiple sclerosis (RRMS) treatment Plegridy (peg interferon beta-1a) by Biogen Idec, has just received Welsh NHS approval, which should…
Not All Snowflakes are the Same – an MS patient’s story
by: Matt Allen G- So I recently decided to make the switch from Tysabri to Lemtrada. I did not talk…
Stuart Schlossman
Biogen Reports Another Tecfidera PML Case
Non-fatal case is the second one for the oral MS drug. by Kristina Fiore Staff Writer, MedPage Today There’s been…
Stuart Schlossman
New MS Study Shows TYSABRI Improves Cognitive Impairment
JULY 13TH, 2015 PATRICIA SILVA, PHD Researchers at Spedali Civili of Brescia in Italy recently published findings in the journalPLoS One that Biogen’s Tysabri (natalizumab) can…
Stuart Schlossman
New treatment for MS now available in the DC area
Thomas James, WUSA4:47 p.m. EDT July 13, 2015 The treatment, called Lemtrada, has been used around the world for several…
Stuart Schlossman
Potential treatment could reduce relapses and disability progression
Pharmaceutical company Roche has announced the completion two phase 3 trials (OPERA I and OPERA II), testing ocrelizumab in people with relapsing…
Stuart Schlossman
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
June 30, 2015 Studies showed superiority on primary and major secondary endpoints in people with relapsing forms of multiple sclerosis Genentech…
Stuart Schlossman
Novartis’ Gilenya Found to Have Long-Term Positive Effects on Patients with Relapsing-Remitting Multiple Sclerosis
A new study recently published in the Journal of Neurology, Neurosurgery and Psychiatryrevealed that long-term fingolimod therapy (marketed as Gilenya by Novartis) can maintain a…
Stuart Schlossman
Finding Hope: Lakeland Woman Recovering From Experimental Treatment for MS
FROM LEFT, Nolen Baker, 4, Steve Baker, Lincoln Baker, 1, and Kristan Baker at their home in Lakeland. PIERRE DUCHARME…
Stuart Schlossman
Non-Insured Health Benefits Program Approves AUBAGIO(TM) for Relapsing Remitting Multiple Sclerosis
Once-daily oral tablet to be reimbursed for first-line use through exception process MISSISSAUGA, ON, June 24, 2015 /CNW/ – Genzyme Canada announced…
Stuart Schlossman
